Craig McDonald, MD — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications5liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
(-)-EpicatechinThis is a 48-week open-label extension of our initial proof-of-concept study (UCD0113) in patients with Becker muscular dystrophy who participated in the earlier trial. This single center study will enroll up to 10 adults who will receive the purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks. After screening visits, participants will be enrolled in the study if they meet all inclusion criteria. They will be evaluated at screening, baseline, and weeks 4, 8, 12, 24, 16 and 48. The main criterion for success of the study will be presence of one or more biologic or strength and performance outcome measures that yield a response magnitude that allows for sufficient power in a Phase II B study with a sample size of 30 individuals.	Myopathies	Phase 2	À vérifier	United States	À vérifier
(-)-EpicatechinThis is a 48-week open-label extension of our initial proof-of-concept study (UCD0113) in patients with Becker muscular dystrophy who participated in the earlier trial. This single center study will enroll up to 10 adults who will receive the purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks. After screening visits, participants will be enrolled in the study if they meet all inclusion criteria. They will be evaluated at screening, baseline, and weeks 4, 8, 12, 24, 16 and 48. The main criterion for success of the study will be presence of one or more biologic or strength and performance outcome measures that yield a response magnitude that allows for sufficient power in a Phase II B study with a sample size of 30 individuals.	Myopathies	Phase 2	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
(-)-Epicatechin	Myopathies	Phase 2	NCT03236662	(-)- Epicatechin Becker Muscular Dystrophy	COMPLETED

Publications

5

Molécule	Indication / population	Titre	Journal	Date
(-)-Epicatechin		Unlocking hypoglycemic effect of black highland barley by targeting α-glucosidase inhibitors based on UF-HPLC-MS /MS.	Talanta
(-)-Epicatechin		Comprehensive phytochemical and pharmacological investigation of Cynoglossum clandestinum desf. ethanolic leaf extract: In vitro, In vivo, and In silico assessment of antioxidant, anti-inflammatory, and antidepressant properties.	Journal of ethnopharmacology
(-)-Epicatechin		flower extract enhances antioxidant defense and wound healing effects in human keratinocytes and fibroblasts.	Pharmaceutical biology
(-)-Epicatechin		Effects of Thermal Aging and Subsequent Autoclave Treatment on the Phytochemical Fingerprint, Antioxidant Capacity, and In Vitro Carbohydrate-Hydrolyzing Enzyme Inhibitory Activity of Lychee Pulp Extracts.	Plants (Basel, Switzerland)
(-)-Epicatechin		Integrated Transcriptomic and Metabolomic Profiling Reveals the Involvement of the miR397-5p-SbLAC14 Module in Condensed Tannin Accumulation in Developing Sorghum Seeds.	Plants (Basel, Switzerland)